{"prompt": "['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', 'The Investigator will enquire about the occurrence of AEs/SAEs at every visit throughout the', 'study (including Follow-up and Early Withdrawal visits where applicable), by asking the', 'following non-leading verbal question of the subject (or care-giver, where appropriate):', '\"Have you had any medical problems since your last visit?\"', \"All AEs not resolved by the end of the study or that have not resolved upon the subject's\", 'discontinuation in the study must be followed until the event resolves, the event stabilizes or the', 'event returns to baseline if a baseline value is available.', '11.4.2.', 'Recording of Adverse Events', 'All AEs, regardless of the seriousness, severity or relationship to the study medication must be', 'recorded on the AE CRF.', 'Adverse events that meet the definition of a SAE must be reported on the SAE Form provided', 'for this study.', 'Adverse events must be documented in clear, unambiguous medical language. Do not use', 'abbreviations or acronyms.', 'For each AE record only the diagnosis, do not report the characteristic signs and symptoms of', 'the diagnosis as additional AEs.', 'If a diagnosis is not available record each sign and symptom as an AE, when a diagnosis', 'becomes available, update the AE CRF, to record the relevant diagnosis only.', \"In general abnormal findings at screening should be recorded in the subject's Medical History or\", 'in the Concurrent Conditions section in the CRF. However if, in the Investigators opinion, the', 'finding is clinically significant and represents a condition that was not present at signing of', 'informed consent, then the finding must be reported as an AE.', '11.5.', 'Reporting Adverse Events', 'Prompt notification of SAEs by the Investigator to Glenmark is essential so that legal obligations', 'and ethical responsibilities towards the safety of subjects are met.', 'Glenmark has a legal responsibility to notify both the local regulatory authority and other', 'regulatory agencies about the safety of a product under clinical investigation. Glenmark will', 'comply with country-specific regulatory requirements relating to safety reporting to the', 'regulatory authority, IRB/IEC and Investigators.', 'All SAEs must be reported to the Sponsor immediately or within 24 hours of the Investigator or', 'their staff becoming aware of them. Reporting should be performed by recording as much', 'information as is available at the time on the SAE Form and sending it to the contact information', 'provided below:', 'Fax:', 'Email:', 'When further information becomes available, the SAE Form should be updated with the new', 'information and reported immediately via the same contact information. Follow-up reports must', 'Glenmark', 'CONFIDENTIAL', 'Page 54 of 90']['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', 'be submitted to the Sponsor until the event resolves, the event stabilizes or the event returns to', 'baseline if a baseline value is available.', 'Additional information will be requested by the Sponsor as necessary.', '11.5.1.', 'Pregnancy', 'The Investigator will attempt to collect pregnancy information on any female partner of a male', 'study subject who becomes pregnant while participating in this study (as applicable). In', 'addition, the underage male subject should also be referred for appropriate evaluation. The', 'Investigator will record pregnancy information on the appropriate form and submit it to the', \"Sponsor within 2 weeks of learning of the partner's pregnancy. The partner will also be\", 'followed to determine the outcome of the pregnancy. Information on the status of the mother', 'and child will be forwarded to the Sponsor. Generally, follow-up will be no longer than 6 to', '8 weeks following the estimated delivery date. Any premature termination of the pregnancy will', 'be reported.', 'Any pregnancy that occurs during study participation must be reported to the Sponsor, using a', 'clinical trial pregnancy form, immediately or within 24 hours of the Investigator learning of its', 'occurrence. The report should contain as much information as possible and should be sent to:', 'Fax:', 'Email:', 'When further information becomes available, the Pregnancy Report Form should be updated', 'with all new information and reported immediately via the same contact information above. The', 'Pregnancy must be followed up to determine outcome (including premature termination) and', 'status of mother and child, and this information must be sent to the Sponsor as above. Pregnancy', 'complications and elective terminations for medical reasons must be reported as an AE or SAE.', 'Spontaneous abortions must be reported as an SAE.', 'Additional information will be requested by the Sponsor as necessary.', \"Any SAE occurring in association with a pregnancy brought to the Investigator's attention after\", 'the subject has completed the study and considered by the Investigator as possibly related to the', 'study drug, must be promptly reported to the Sponsor.', 'Glenmark', 'CONFIDENTIAL', 'Page 55 of 90']\n\n###\n\n", "completion": "END"}